Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma

Despite multimodal treatments comprising, radiation therapy (RT) and chemotherapy with temozolomide (TMZ), the prognosis of glioblastoma multiforme (GBM) remains dismal and consolidated therapy yields a median survival of 14.6 months. Blood Brain Barrier (BBB) mediated chemoresistance and high dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Iorio, Anna Lisa, da Ros, Martina, Genitori, Lorenzo, Lucchesi, Maurizio, Colelli, Fabiana, Signorino, Giacomo, Cardile, Francesco, Laffi, Giacomo, de Martino, Maurizio, Pisano, Claudio, Sardi, Iacopo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685694/
https://www.ncbi.nlm.nih.gov/pubmed/29163773
http://dx.doi.org/10.18632/oncotarget.19875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685694/
https://www.ncbi.nlm.nih.gov/pubmed/29163773
http://dx.doi.org/10.18632/oncotarget.19875

Ejemplares similares